In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays
Journal of Thrombosis and Haemostasis · 2023
DOI: 10.1016/j.jtha.2023.03.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Jacob Lund und 3 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Måløv, Denmark. Electronic address: jcld@novonordisk.com. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
BACKGROUND: Mim8 is a novel antifactor IXa/antifactor X bispecific antibody in clinical development for prophylactic treatment of hemophilia A with and without inhibitors. Patients treated with Mim8 may need supplementary bleed treatment under certain conditions such as surgery or major trauma. OBJECTIVES: This study aimed to better understand the response of Mim8 in thrombin generation assays (TGAs) alone or in combination with other hemostatic proteins. METHODS: We used TGAs with different activators (tissue factor (TF) and activated factor XI) to better understand the similarities and differences between the mode of action of Mim8 and factor VIII (FVIII). Following this, we investigated the effects of mixing Mim8 with the main bleed treatment options for persons with hemophilia A with or without inhibitors: FVIII, activated factor VII (FVIIa), and activated prothrombin complex concentrates (aPCC). RESULTS: The results indicated that for patients without inhibitors, Mim8 does not interfere with FVIII's mode of action. For patients with inhibitors, Mim8 mixed with aPCC results in a strong synergistic effect causing thrombin generation far exceeding the normal levels. Contrary to this, mixing Mim8 with FVIIa results in a more controlled additive effect, visible only when using TF as a trigger, which does not exceed the normal level of thrombin generation. CONCLUSION: These findings support the use of approved clinical doses of FVIIa for bleed treatment of patients with FVIII inhibitors treated with Mim8. Additionally, the findings suggest that concomitant use of FVIII and Mim8 is safe for managing breakthrough bleeds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk A/S, Måløv, Denmark. Electronic address: jcld@novonordisk.com.
- Novo Nordisk A/S, Måløv, Denmark.
Förderung
- Novo Nordisk
Zitieren
APA
Lund, J., Jensen, K., Burnier, L., & Ezban, M. (2023). In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.03.007
Vancouver
Lund J, Jensen K, Burnier L, Ezban M. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.03.007
BibTeX
@article{Lund2023,
author = {Lund, Jacob and Jensen, Kasper and Burnier, Laurent and Ezban, Mirella},
title = {In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
doi = {10.1016/j.jtha.2023.03.007}
}
EUVIMED